Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (281)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00641706 | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00597402 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | completed | Phase 2 | 125 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00677716 | Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse | completed | Phase 2 | 41 | Peregrine PharmaceuticalsINDUSTRY | 2 | Apr 24, 2014 | clinicaltrials |
| NCT00397072 | Epothilone in Recurrent Glioblastoma Patients | completed | Phase 2 | 15 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00979017 | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | completed | Phase 2 | 41 | Katy PetersOTHER | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00657267 | Dose-Intense Temozolomide in Recurrent Glioblastoma | completed | Phase 2 | 58 | Patrick Y. Wen, MDOTHER | 1 | Mar 14, 2014 | clinicaltrials |
| NCT00611325 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | completed | Phase 2 | 56 | Duke UniversityOTHER | 1 | Mar 12, 2014 | clinicaltrials |
| NCT00337883 | A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) | completed | Phase 2 | 110 | Genentech, Inc.INDUSTRY | 0 | Mar 4, 2014 | clinicaltrials |
| NCT00575887 | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma | completed | Phase 2 | 25 | Marmara UniversityOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00921167 | A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas | completed | Phase 2 | 32 | Clinical Research Center for Solid Tumor, KoreaOTHER | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00431561 | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma | completed | Phase 2 | 141 | Isarna Therapeutics GmbHINDUSTRY | 6 | Dec 3, 2013 | clinicaltrials |
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme(COGLI) | terminated | Phase 1 / Phase 2 | 2 | Baylor College of MedicineOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00305656 | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Aug 22, 2013 | clinicaltrials |
| NCT00612430 | Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | completed | Phase 2 | 59 | Duke UniversityOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00672243 | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00039494 | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | completed | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00016328 | CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00014170 | Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00613028 | Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | completed | Phase 2 | 23 | Duke UniversityOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00870181 | ADV-TK Improves Outcome of Recurrent High-Grade Glioma(HGG-01) | completed | Phase 2 | 47 | Huazhong University of Science and TechnologyOTHER | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00597493 | Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00939991 | Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 48 | Katy PetersOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT01115036 | A Panobinostat Presurgery(CLBH589C) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01095094 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | terminated | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00501891 | Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00612339 | Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | completed | Phase 2 | 41 | Duke UniversityOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00671970 | Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | completed | Phase 2 | 57 | Duke UniversityOTHER | 1 | May 13, 2013 | clinicaltrials |
| NCT01011231 | Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma(GKS) | terminated | Phase 2 | 1 | University of California, San FranciscoOTHER | 1 | May 6, 2013 | clinicaltrials |
| NCT00650949 | Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma | terminated | Phase 1 / Phase 2 | 20 | Gilead SciencesINDUSTRY | 1 | May 3, 2013 | clinicaltrials |
| NCT00058097 | Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00615927 | Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | completed | Phase 2 | 64 | Duke UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01100177 | Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients | completed | Phase 2 | 12 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 11, 2013 | clinicaltrials |
| NCT00959946 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | PfizerINDUSTRY | 6 | Feb 22, 2013 | clinicaltrials |
| NCT00735436 | A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 18 | Duke UniversityOTHER | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00005856 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00075491 | Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme | terminated | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00354913 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00190424 | Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma | completed | Phase 2 | 80 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 13, 2012 | clinicaltrials |
| NCT00797940 | Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)(CLARITY-1) | withdrawn | Phase 2 | 0 | Sophiris Bio CorpINDUSTRY | 0 | Dec 3, 2012 | clinicaltrials |
| NCT01737346 | Procarbazine and Lomustine in Recurrent Glioblastoma | unknown | Phase 2 | 52 | Incheon St.Mary's HospitalOTHER | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00606008 | A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT00409214 | Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma | completed | Phase 2 | 18 | Light Sciences OncologyINDUSTRY | 1 | Nov 16, 2012 | clinicaltrials |
| NCT01251484 | BIBF 1120 in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 25 | Ulrik LassenOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT00948389 | Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | terminated | Phase 1 / Phase 2 | 28 | Bristol-Myers SquibbINDUSTRY | 4 | Aug 31, 2012 | clinicaltrials |
| NCT00624728 | Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)(GLIO-TEP) | completed | Phase 1 / Phase 2 | 21 | University Hospital, BordeauxOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT01285414 | Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 5 | Myrexis Inc.INDUSTRY | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00412542 | Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT00071539 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | completed | Phase 2 | 56 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | Jan 20, 2012 | clinicaltrials |
| NCT00504660 | 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 11, 2012 | clinicaltrials |
Data updated 23 days agoSource updated May 14, 2014source: clinicaltrials